Digestive and Endocrine Surgery Department, Magellan Center, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France.
Endocrinology Department, INSERM Unit 1215, Bordeaux University Hospital, University of Bordeaux, Bordeaux, France.
World J Surg. 2022 Nov;46(11):2666-2675. doi: 10.1007/s00268-022-06633-7. Epub 2022 Jun 29.
Multiple endocrine neoplasia type 1 (MEN1)-associated primary hyperparathyroidism (pHPT) is classically associated with an asymmetric and asynchronous parathyroid involvement. Subtotal parathyroidectomy (STP), which is currently the recommended surgical treatment, carries a high risk of permanent hypoparathyroidism. The results of less than subtotal parathyroidectomy (LSTP) are conflicting, and its place in this setting is still a matter of debate. The aim of this study was to identify the place of LSTP in the surgical management of patients with MEN-associated pHPT.
A systematic literature review was conducted in accordance with PRISMA and MOOSE guidelines, for studies comparing STP and LSTP for MEN1-associated pHPT. The results of the two techniques, regarding permanent hypoparathyroidism, persistent hyperparathyroidism and recurrent hyperparathyroidism were computed using pairwise random-effect meta-analysis.
Twenty-five studies comparing STP and LSTP qualified for inclusion in the quantitative synthesis. In total, 947 patients with MEN1-associated pHPT were allocated to STP (n = 569) or LSTP (n = 378). LSTP reduces the risk of permanent hypoparathyroidism [odds ratio (OR) 0.29, confidence interval (CI) 95% 0.17-0.49)], but exposes to higher rates of persistent hyperparathyroidism [OR 4.60, 95% CI 2.66-7.97]. Rates of recurrent hyperparathyroidism were not significantly different between the two groups [OR 1.26, CI 95% 0.83-1.91].
LSTP should not be abandoned and should be considered as a suitable surgical option for selected patients with MEN1-associated pHPT. The increased risk of persistent hyperparathyroidism could improve with the emergence of more efficient preoperative localization imaging techniques and a more adequate patients selection.
多发性内分泌腺瘤病 1 型(MEN1)相关的原发性甲状旁腺功能亢进症(pHPT)通常与甲状旁腺的不对称和不同步受累有关。次全甲状旁腺切除术(STP)是目前推荐的手术治疗方法,但有发生永久性甲状旁腺功能减退的高风险。少于次全甲状旁腺切除术(LSTP)的结果存在争议,其在这种情况下的地位仍存在争议。本研究旨在确定 LSTP 在 MEN 相关 pHPT 患者的手术治疗中的地位。
根据 PRISMA 和 MOOSE 指南进行系统文献回顾,以比较 STP 和 LSTP 治疗 MEN1 相关 pHPT 的研究。使用配对随机效应荟萃分析计算两种技术在永久性甲状旁腺功能减退、持续性甲状旁腺功能亢进和复发性甲状旁腺功能亢进方面的结果。
25 项比较 STP 和 LSTP 的研究符合纳入定量综合的标准。共有 947 名 MEN1 相关 pHPT 患者被分配至 STP(n=569)或 LSTP(n=378)组。LSTP 降低永久性甲状旁腺功能减退的风险[比值比(OR)0.29,95%置信区间(CI)0.17-0.49],但增加持续性甲状旁腺功能亢进的风险[OR 4.60,95%CI 2.66-7.97]。两组间复发性甲状旁腺功能亢进的发生率无显著差异[OR 1.26,95%CI 0.83-1.91]。
不应放弃 LSTP,应将其视为 MEN1 相关 pHPT 患者的一种合适的手术选择。随着更有效的术前定位成像技术和更充分的患者选择的出现,持续性甲状旁腺功能亢进的风险可能会降低。